Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4250869 | 0.95 | CNR1 (0.91) | CNR1CNR2 | |
| SCHEMBL922625 | 0.95 | CNR1 (0.90) | CNR1CNR2 | |
| SCHEMBL22449360 | 0.94 | CNR1 (0.89) | CNR1CNR2 | |
| SCHEMBL14155463 | 0.93 | CNR1 (0.88) | CNR1CNR2 | |
| SCHEMBL4904806 | 0.92 | CNR1 (0.86) | CNR1CNR2 | |
| SCHEMBL4911621 | 0.92 | CNR1 (0.86) | CNR1CNR2 | |
| SCHEMBL4589362 | 0.92 | CNR1 (0.86) | CNR1CNR2 | |
| SCHEMBL12053752 | 0.90 | CNR1 (0.82) | CNR1CNR2 | |
| SCHEMBL25239033 | 0.90 | CNR1 (0.82) | CNR1CNR2 | |
| SCHEMBL14247148 | 0.90 | CNR1 (0.82) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133904-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity | JENRIN DISCOVERY, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8088798-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity | Jensen Discovery, Inc. | 2012-01-03 | — | — | US | disclosed |
| US-20100144791-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2010-06-10 | — | — | US | disclosed |
| US-7687481-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity | JENRIN DISCOVERY, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090069329-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2009-03-12 | — | — | US | disclosed |
| US-20070213302-A1 | pyrazoles; diabetes, cardiometabolic disorders; side effects reduction | JENRIN DISCOVERY (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144791-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | CNR2, CNR1, GPR119 | CNR1 2/4885CNR2 1/4885 |
| US-20090069329-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | CNR2, CNR1, GPR119 | CNR1 2/4885CNR2 1/4885 |
| US-20070213302-A1 | pyrazoles; diabetes, cardiometabolic disorders; side effects reduction | CNR2, CNR1, GPR119 | CNR1 2/4885CNR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.